Carna Biosciences, Inc.
Climate Impact & Sustainability Data (2024)
Reporting Period: 2024
Environmental Metrics
Social Achievements
- Sponsorship to CLL Society to promote patient enrollment in docirbrutinib clinical trial.
Climate Goals & Targets
Environmental Challenges
- Overall sales declined due to drastic decrease of overseas sales than expected including in the U.S. and China.
- Economic recession and the possibility of restraint of trade with Chinese biotech companies by the U.S. government had negative impacts on Chinese market and the start of production of kinase protein by some Chinese CROs also caused the continuous reduction in demand in China.
Mitigation Strategies
- Raised additional capital through the 3rd party allotment of common shares in May and in October.
- Additional financing may be considered as necessary in order to accelerate the clinical trials of docirbrutinib (AS-1763), our most important asset.